What Is Praxis Precision Medicines, Inc (PRAX) Worth in 2026?
According to the CirclFi Deep Alpha Valuation Engine, Praxis Precision Medicines, Inc's intrinsic value is estimated at $94.89, suggesting the stock is overvalued at its current price of $318.42. With 11 out of 12 models flagging downside (-70.2% average return), the market may be pricing in unsustainable growth. The most optimistic model, PWERM, places fair value at $323.11 (+1.5%), while ML-RIV — the most conservative — estimates $15.26 (-95.2%). This +96.7% gap reflects genuine analytical uncertainty about Praxis Precision Medicines, Inc's intrinsic worth.
What Do the Models Say About PRAX?
12 of 13 models are currently active for PRAX. Of these, 1 model suggests upside while 11 models suggest overvaluation. The Bayesian DCF estimates PRAX's intrinsic value at $108.35, implying -66.0% downside from the current price. See which stocks rank higher →
How Does PRAX Rank in Pharmaceutical Preparations?
Among 431 Pharmaceutical Preparations stocks, PRAX ranks #187 by Quality of Company score. CirclFi's QOC score of 5.2/10 evaluates 32 fundamental signals. A score of 5.2 reflects mixed fundamentals.
See all Most Undervalued Pharmaceutical Preparations Stocks →
Within the Pharmaceutical Preparations space, Praxis Precision Medicines, Inc competes in an environment where FDA approval probability often separates market leaders from laggards. Understanding these industry-specific dynamics is essential context for interpreting our model outputs.
Is PRAX a Value Trap?
CirclFi's Value Trap algorithm assigns PRAX a score of 24/100 (SAFE). This indicates minimal risk. Fundamentals are healthy. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →
Multi-Model Methodology
12 of 13 models are active for Praxis Precision Medicines, Inc. Broad coverage provides high confidence. Each model applies a fundamentally different valuation philosophy. See the complete methodology →
According to the CirclFi Quality of Company (QOC) framework, which evaluates 32 signals including margin stability, revenue growth trajectory, leverage, and free cash flow generation, Praxis Precision Medicines, Inc is rated at 5.2/10. This moderate-tier score shows mixed signals across our quality framework with notable weaknesses.
The gap between the most bullish and bearish model spans +96.7% — demonstrating why single-model analysis is dangerous. Browse all stocks with 13-model coverage →
Data Sources & Confidence
Every PRAX valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →
Across PRAX's 12 active models, average confidence is 36%. Lower confidence may reflect limited history or high volatility.
CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →
Buy with Gumroad